Skip to content

Imaginostics

2 viewers · 30d

Total raised

$7.2M

+$40K this year

8 filings since 2018 · latest Equity filed

Cumulative raised
LAST ROUND
Equity · $40K
ROUNDS
8
INVESTORS
5
FOUNDED
N/A
HQ
Orlando, FL
SECTOR
Healthcare
EMPLOYEES
N/A
30D VIEWERS
2

AI overview

Updated

Imaginostics is a medical imaging diagnostics company developing QUTE-CE MRI (Quantitative Ultra-short Time-to-Echo Contrast-Enhanced magnetic resonance imaging), a technique that turns standard MRI scanners into quantitative instruments for measuring blood vessels in the brain. Its software produces per-patient maps of microvascular structure, vasodilatory function, and blood-brain-barrier leakage from a single scan on existing hardware, using a ferumoxytol-class contrast agent instead of gadolinium. The lead indication is early detection and stratification of Alzheimer's disease and related dementias, with a pivotal clinical study run at Brigham and Women's Hospital in Boston. The company was founded in July 2018 by Valerie Gharagouzloo and Dr. Codi Amir Gharagouzloo, and received FDA Breakthrough Device Designation in October 2024.

What sets it apart

The platform is software on top of MRI scanners hospitals already own - no new hardware - and it avoids gadolinium, which makes it usable in chronic kidney disease patients who are excluded from contrast MRI today. Its vascular biomarkers are claimed to surface Alzheimer's-related changes long before symptom onset, and it carries FDA Breakthrough Device Designation plus NIH and Alzheimer's Drug Discovery Foundation backing.

Funding history

8 rounds
Equity+3May 14, 2026
Form D
+$40K$7.2M total
Equity+3Feb 3, 2024
Form D
+$5.4M$7.1M total
Equity+3Sep 6, 2022
Form D
+$725K$1.8M total
Equity+3Nov 20, 2021
Form D/A
+$50K$1.1M total
Equity+3Nov 20, 2021
Form D
+$500K$1.0M total
Equity+3Feb 9, 2021
Form D
+$517K$1.0M total
Equity+3Sep 3, 2020
Form D
+$100K$500K total
EquityJul 21, 2018
Form D
+$400K$400K total

Products

1 tracked

QUTE-CE MRI

Diagnostic imaging software and device

A quantitative contrast-enhanced MRI method and accompanying imaging software that generates individual-patient maps of vascular microstructure, vasodilatory function, and blood-brain-barrier permeability from a single scan on an existing MRI scanner.

  • Runs on existing MRI scanners with no hardware changes
  • Quantitative maps of microvascular density, vessel structure, and blood-brain-barrier leakage
  • Gadolinium-free contrast, usable in chronic kidney disease stages 3-5
  • Reported roughly 10x improvement in soft-tissue image quality as judged by radiologists

Links

WebsiteSEC EDGAR filings